{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T13:57:02Z","timestamp":1760709422591,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81641167"],"award-info":[{"award-number":["81641167"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12951-017-0302-5","type":"journal-article","created":{"date-parts":[[2017,10,4]],"date-time":"2017-10-04T08:06:24Z","timestamp":1507104384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["mAb MDR1-modified chitosan nanoparticles overcome acquired EGFR-TKI resistance through two potential therapeutic targets modulation of MDR1 and autophagy"],"prefix":"10.1186","volume":"15","author":[{"given":"Yan","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijie","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,4]]},"reference":[{"issue":"8","key":"302_CR1","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s40265-017-0734-0","volume":"77","author":"J Moreira","year":"2017","unstructured":"Moreira J, Tobias A, O\u2019Brien MP, Agulnik M. Targeted therapy in head and neck cancer: an update on current clinical developments in epidermal growth factor receptor-targeted therapy and immunotherapies. Drugs. 2017;77(8):843\u201357.","journal-title":"Drugs."},{"issue":"2","key":"302_CR2","first-page":"187","volume":"7","author":"TC Liu","year":"2017","unstructured":"Liu TC, Jin X, Wang Y, Wang K. Role of epidermal growth factor receptor in lung cancer and targeted therapies. Am J Cancer Res. 2017;7(2):187\u2013202.","journal-title":"Am J Cancer Res."},{"key":"302_CR3","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/319226a0","volume":"319","author":"CI Bargmann","year":"1986","unstructured":"Bargmann CI, Hung MC, Weinberg RA. The neuoncogene encodes an epidermal growth factor receptor-related protein. Nature. 1986;319:226\u201330.","journal-title":"Nature"},{"issue":"4","key":"302_CR4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/14740338.2017.1300656","volume":"16","author":"MJ Ahn","year":"2017","unstructured":"Ahn MJ, Sun JM, Lee SH, et al. EGFR TKI combination with immunotherapy in non-small cell lung cancer. Expert Opin Drug Saf. 2017;16(4):465\u20139.","journal-title":"Expert Opin Drug Saf."},{"key":"302_CR5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cllc.2011.08.005","volume":"13","author":"F Petrelli","year":"2012","unstructured":"Petrelli F, Borgonovo K, Cabiddu M, Barni S. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials. Clin Lung Cancer. 2012;13:107\u201314.","journal-title":"Clin Lung Cancer."},{"issue":"2","key":"302_CR6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1517\/14656566.2016.1109635","volume":"17","author":"S Mitsuoka","year":"2016","unstructured":"Mitsuoka S, Kawaguchi T, Kubo A, et al. Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR. Expert Opin Pharmacother. 2016;17(2):193\u2013203.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"302_CR7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.cllc.2015.11.009","volume":"17","author":"J Xu","year":"2016","unstructured":"Xu J, Chu T, Jin B, et al. Epidermal growth factor receptor tyrosine kinase inhibitors in advanced squamous cell lung cancer. Clin Lung Cancer. 2016;17(4):309\u201314.","journal-title":"Clin Lung Cancer."},{"issue":"7","key":"302_CR8","first-page":"10330","volume":"8","author":"L Ge","year":"2015","unstructured":"Ge L, Shi R. Progress of EGFR-TKI and ALK\/ROS1 inhibitors in advanced non-small cell lung cancer. Int J Clin Exp Med. 2015;8(7):10330\u20139.","journal-title":"Int J Clin Exp Med."},{"issue":"11","key":"302_CR9","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1586\/era.12.121","volume":"12","author":"M Bartolotti","year":"2012","unstructured":"Bartolotti M, Franceschi E, Brandes AA. EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer. Expert Rev Anticancer Ther. 2012;12(11):1429\u201335.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"302_CR10","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1517\/14740338.2011.617738","volume":"10","author":"A D\u2019Incecco","year":"2011","unstructured":"D\u2019Incecco A, Cappuzzo F. Gefitinib for non-small-cell lung cancer treatment. Expert Opin Drug Saf. 2011;10(6):987\u201396.","journal-title":"Expert Opin Drug Saf."},{"issue":"10","key":"302_CR11","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1158\/0008-5472.CAN-12-4136","volume":"73","author":"K Shien","year":"2013","unstructured":"Shien K, Toyooka S, Yamamoto H, et al. Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell\u2013like properties in cancer cells. Cancer Res. 2013;73(10):3051\u201361.","journal-title":"Cancer Res"},{"key":"302_CR12","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-10-2692","volume":"17","author":"GR Oxnard","year":"2011","unstructured":"Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 2011;17:1616\u201322.","journal-title":"Clin Cancer Res"},{"issue":"Supplement","key":"302_CR13","doi-asserted-by":"crossref","first-page":"C131","DOI":"10.4103\/0973-1482.200613","volume":"12","author":"K Zhang","year":"2016","unstructured":"Zhang K, Yuan Q. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer. J Cancer Res Ther. 2016;12(Supplement):C131\u20137.","journal-title":"J Cancer Res Ther."},{"issue":"5","key":"302_CR14","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.3892\/ol.2016.5193","volume":"12","author":"G Al\u00ec","year":"2016","unstructured":"Al\u00ec G, Bruno R, Giordano M, et al. Small cell lung cancer transformation and the T790M mutation: a case report of two acquired mechanisms of TKI resistance detected in a tumor rebiopsy and plasma sample of EGFR-mutant lung adenocarcinoma. Oncol Lett. 2016;12(5):4009\u201312.","journal-title":"Oncol Lett."},{"key":"302_CR15","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1186\/s12885-015-1543-z","volume":"15","author":"HJ Kim","year":"2015","unstructured":"Kim HJ, Lee KY, Kim YW, et al. P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangement. BMC Cancer. 2015;15:553.","journal-title":"BMC Cancer."},{"issue":"4","key":"302_CR16","first-page":"287","volume":"35","author":"AA Kovalev","year":"2013","unstructured":"Kovalev AA, Tsvetaeva DA, Grudinskaja TV. Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer. Exp Oncol. 2013;35(4):287\u201390.","journal-title":"Exp Oncol."},{"issue":"3","key":"302_CR17","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ajpath.2011.11.029","volume":"180","author":"K Akiyama","year":"2012","unstructured":"Akiyama K, Ohga N, Hida Y, et al. Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment. Am J Pathol. 2012;180(3):1283\u201393.","journal-title":"Am J Pathol"},{"issue":"2","key":"302_CR18","doi-asserted-by":"crossref","first-page":"110","DOI":"10.5732\/cjc.011.10327","volume":"31","author":"XX Peng","year":"2012","unstructured":"Peng XX, Tiwari AK, Wu HC, Chen ZS. Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells. Chin J Cancer. 2012;31(2):110\u20138.","journal-title":"Chin J Cancer."},{"issue":"8","key":"302_CR19","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/ijc.26190","volume":"130","author":"B Boyerinas","year":"2012","unstructured":"Boyerinas B, Park SM, Murmann AE, et al. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer. 2012;130(8):1787\u201397.","journal-title":"Int J Cancer"},{"issue":"1","key":"302_CR20","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1186\/s12885-016-2790-3","volume":"16","author":"B Guo","year":"2016","unstructured":"Guo B, Tam A, Santi SA, Parissenti AM. Role of autophagy and lysosomal drug sequestration in acquired resistance to doxorubicin in MCF-7 cells. BMC Cancer. 2016;16(1):762.","journal-title":"BMC Cancer."},{"key":"302_CR21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.biopha.2016.04.054","volume":"82","author":"B Liang","year":"2016","unstructured":"Liang B, Liu X, Liu Y, et al. Inhibition of autophagy sensitizes MDR-phenotype ovarian cancer SKVCR cells to chemotherapy. Biomed Pharmacother. 2016;82:98\u2013105.","journal-title":"Biomed Pharmacother"},{"key":"302_CR22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12951-015-0121-5","volume":"13","author":"L Zhao","year":"2015","unstructured":"Zhao L, Yang G, Shi Y, et al. Co-delivery of gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance. J Nanobiotechnol. 2015;13:57.","journal-title":"J Nanobiotechnol"},{"issue":"8","key":"302_CR23","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/cas.12712","volume":"106","author":"Q Tan","year":"2015","unstructured":"Tan Q, Wang H, Hu Y, et al. Src\/STAT3-dependent heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy. Cancer Sci. 2015;106(8):1023\u201332.","journal-title":"Cancer Sci"},{"issue":"13","key":"302_CR24","doi-asserted-by":"crossref","first-page":"9165","DOI":"10.1074\/jbc.M112.422071","volume":"288","author":"S Desai","year":"2013","unstructured":"Desai S, Liu Z, Yao J, et al. Heat shock factor 1 (HSF1) controls chemoresistance and autophagy through transcriptional regulation of autophagy-related protein 7 (ATG7). J Biol Chem. 2013;288(13):9165\u201376.","journal-title":"J Biol Chem"},{"issue":"2","key":"302_CR25","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.freeradbiomed.2011.10.487","volume":"52","author":"CJ Lin","year":"2012","unstructured":"Lin CJ, Lee CC, Shih YL, et al. Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radic Biol Med. 2012;52(2):377\u201391.","journal-title":"Free Radic Biol Med."},{"issue":"1","key":"302_CR26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12951-017-0261-x","volume":"15","author":"Y Zheng","year":"2017","unstructured":"Zheng Y, Su C, Zhao L, Shi Y. Chitosan nanoparticle-mediated co-delivery of shAtg-5 and gefitinib synergistically promoted the efficacy of chemotherapeutics through the modulation of autophagy. J Nanobiotechnol. 2017;15(1):28.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"302_CR27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12951-016-0245-2","volume":"15","author":"T Wang","year":"2017","unstructured":"Wang T, Hou J, Su C, et al. Hyaluronic acid-coated chitosan nanoparticles induce ROS-mediated tumor cell apoptosis and enhance antitumor efficiency by targeted drug delivery via CD44. J Nanobiotechnol. 2017;15(1):7.","journal-title":"J Nanobiotechnol"},{"key":"302_CR28","first-page":"245","volume":"10","author":"L Zhao","year":"2015","unstructured":"Zhao L, Li H, Shi Y, et al. Nanoparticles inhibit cancer cell invasion and enhance antitumor efficiency by targeted drug delivery via cell surface-related GRP78. Int J Nanomed. 2015;10:245.","journal-title":"Int J Nanomed"},{"issue":"5","key":"302_CR29","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1185\/03007995.2015.1025731","volume":"31","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Liao Z, Zhang LJ, Xiao HT. The utility of chloroquine in cancer therapy. Curr Med Res Opin. 2015;31(5):1009\u201313.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"302_CR30","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0006-2952(00)00270-7","volume":"59","author":"M Vezmar","year":"2000","unstructured":"Vezmar M, Georges E. Reversal of MRP-mediated doxorubicin resistance with quinoline-based drugs. Biochem Pharmacol. 2000;59(10):1245\u201352.","journal-title":"Biochem Pharmacol"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-017-0302-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T03:27:28Z","timestamp":1570159648000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-017-0302-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,4]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["302"],"URL":"https:\/\/doi.org\/10.1186\/s12951-017-0302-5","relation":{},"ISSN":["1477-3155"],"issn-type":[{"type":"electronic","value":"1477-3155"}],"subject":[],"published":{"date-parts":[[2017,10,4]]},"article-number":"66"}}